EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies

Zhongqin Chen iD, Xiaojie Su, Wenhong Cao, Mingtang Tan, Guoping Zhu, Jialong Gao, Longjian Zhou iD

Marine Drugs · 09.08.2024 · 22 (8) · 361

DOI: 10.3390/md22080361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Marine Drugs, online erschienen am 09.08.2024. Verfasst von Zhongqin Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Institute of Guangdong Ocean University, Shenzhen 518120, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Molecular Docking Simulation, Dipeptidyl Peptidase 4. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, the National Natural Science Foundation of China, the Zhanjiang Marine Youth Talent Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of dipeptidyl peptidase-IV (DPP-IV) is a promising approach for regulating the blood glucose levels in patients with type 2 diabetes (T2D). Oysters, rich in functional peptides, contain peptides capable of inhibiting DPP-IV activity. This study aims to identify the hypoglycemic peptides from oysters and investigate their potential anti-T2D targets and mechanisms. This research utilized virtual screening for the peptide selection, followed by in vitro DPP-IV activity assays to validate the chosen peptide. Network pharmacology was employed to identify the potential targets, GO terms, and KEGG pathways. Molecular docking and molecular dynamics simulations were used to provide virtual confirmation. The virtual screening identified LRGFGNPPT as the most promising peptide among the screened oyster peptides. The in vitro studies confirmed its inhibitory effect on DPP-IV activity. Network pharmacology revealed that LRGFGNPPT exerts an anti-T2D effect through multiple targets and signaling pathways. The key hub targets are AKT1, ACE, and REN. Additionally, the molecular docking results showed that LRGFGNPPT exhibited a strong binding affinity with targets like AKT1, ACE, and REN, which was further confirmed by the molecular dynamics simulations showcasing a stable peptide–target interaction. This study highlights the potential of LRGFGNPPT as a natural anti-T2D peptide, providing valuable insights for potential future pharmaceutical or dietary interventions in T2D management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsMolecular Docking SimulationDipeptidyl Peptidase 4PeptidesAnimalsHumansMolecular Dynamics SimulationHypoglycemic AgentsOstreidaeNetwork PharmacologyDrug Discovery

Stichwörter der Autor:innen

DPP-IVmolecular dockingmolecular dynamics simulationnetwork pharmacologyoyster peptidestype 2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4PeptidesHypoglycemic Agents

Autor:innen und Institutionen

  • Shenzhen Institute of Guangdong Ocean University, Shenzhen 518120, China.
  • Guangdong Provincial Key Laboratory of Aquatic Products Processing and Safety, Guangdong Province Engineering Laboratory for Marine Biological Products, Zhanjiang Municipal Key Laboratory of Marine Drugs and Nutrition f…
  • Collaborative Innovation Center of Seafood Deep Processing, Dalian Polytechnic University, Dalian 116034, China.

ORCID-Profile: Zhongqin Chen, Longjian Zhou

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • the National Natural Science Foundation of China
  • the Zhanjiang Marine Youth Talent Innovation Project
  • the Science and Technology Plan Project of Zhanjiang City
  • the Program for scientific research start-up funds of Guangdong Ocean University
  • the Innovative Team Program of High Education of Guangdong Province

Zitieren

APA

Chen, Z., Su, X., Cao, W., Tan, M., Zhu, G., Gao, J., & Zhou, L. (2024). The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies. Marine Drugs, 22(8), 361. https://doi.org/10.3390/md22080361

Vancouver

Chen Z, Su X, Cao W, Tan M, Zhu G, Gao J, et al. The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies. Marine Drugs. 2024;22(8):361. doi:10.3390/md22080361

BibTeX
@article{Chen2024,
  author = {Chen, Zhongqin and Su, Xiaojie and Cao, Wenhong and Tan, Mingtang and Zhu, Guoping and Gao, Jialong and Zhou, Longjian},
  title = {The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies},
  journal = {Marine Drugs},
  year = {2024},
  volume = {22},
  number = {8},
  pages = {361},
  doi = {10.3390/md22080361}
}
Kostenlos starten →